Innate Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Innate Pharma and buy or sell other stocks, ETFs, and their options commission-free!About IPHA
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62.
CEOJonathan Dickinson
CEOJonathan Dickinson
Employees181
Employees181
HeadquartersMarseille, Provence-Alpes-Cote-dAzur
HeadquartersMarseille, Provence-Alpes-Cote-dAzur
Founded1999
Founded1999
Employees181
Employees181
IPHA Key Statistics
Market cap175.00M
Market cap175.00M
Price-Earnings ratio-3.11
Price-Earnings ratio-3.11
Dividend yield—
Dividend yield—
Average volume16.24K
Average volume16.24K
High today$1.85
High today$1.85
Low today$1.84
Low today$1.84
Open price$1.84
Open price$1.84
Volume7.22K
Volume7.22K
52 Week high$3.51
52 Week high$3.51
52 Week low$1.47
52 Week low$1.47
Stock Snapshot
Innate Pharma(IPHA) stock is priced at $1.84, giving the company a market capitalization of 175M. It carries a P/E multiple of -3.11.
On 2025-12-15, Innate Pharma(IPHA) stock moved within a range of $1.84 to $1.85. With shares now at $1.84, the stock is trading +0.2% above its intraday low and -0.3% below the session's peak.
Trading volume for Innate Pharma(IPHA) stock has reached 7.22K, versus its average volume of 16.24K.
Over the past 52 weeks, Innate Pharma(IPHA) stock has traded between a high of $3.51 and a low of $1.47.
Over the past 52 weeks, Innate Pharma(IPHA) stock has traded between a high of $3.51 and a low of $1.47.
Analyst ratings
67%
of 6 ratingsBuy
66.7%
Hold
33.3%
Sell
0%